Wu: She had been tweeting about this, and I knew she would supply some actually balanced perspective right here. First issues first: She has gotten the vaccine. There’s actually no undoing that. However she’s not spending all of her time worrying about getting a clot—partly as a result of that received’t have an effect on whether or not or not she does—but additionally as a result of these circumstances have to this point been actually, actually uncommon. I don’t suppose we but have sufficient info to say they’re going to look in precisely X share of individuals, however it’s most likely going to be a very low quantity.
Higgins: What are the signs to search for in that very uncommon case?
Wu: There’s an inventory that the CDC and FDA put out. They mentioned should you develop extreme complications, stomach ache, leg ache, or shortness of breath inside three weeks of your injection, attain out to your health-care supplier. However that’s going to be the subsequent degree up from the anticipated unintended effects that some individuals would possibly get throughout the first couple of days after getting their injection, which could embrace a light headache. So there’s a little bit little bit of subjectivity there, however hopefully persons are simply maintaining an eye fixed out in these three weeks. That’s the important window we’re right here.
Hamblin: Do you suppose this has been dealt with accurately? Do you suppose pausing Johnson & Johnson for everybody was the suitable transfer?
Wu: That’s a tough query to reply, however I believe I lean on the aspect of “sure.” Think about if the CDC and FDA had waited till it was 20 circumstances, or 30 circumstances, or 100 circumstances … [they] would have gotten questions on why they didn’t pause it when it was simply six and we might have prevented 94 extra circumstances.
I believe they noticed a sign and never only a random cluster of blood clots [that] all seemed so related on this demographic slice of the inhabitants. And they also acted rapidly. This pause might simply be a matter of days to get readability and guarantee that persons are conscious and looking for it. I wouldn’t be shocked if extra circumstances come up as a result of we now know to search for it. [But] they don’t seem to be hoping to completely derail this vaccine.
Hamblin: Do you suppose this pause—assuming it doesn’t pan out to be over a serious danger issue and Johnson & Johnson will get again on-line—will, over time, result in vaccine hesitancy of the kind that we’ve seen with AstraZeneca in Europe? How involved are you about it exacerbating what we’ve already seen within the U.S.?
Wu: I’m involved about this, however I don’t wish to bounce to conclusions about how hesitancy will probably be affected. It’s so tough as a result of exacerbating hesitancy can happen in a mess of how. One is: Folks hear one thing destructive in regards to the vaccine they usually really feel much less good about taking it. One other is that specialists conceal one thing in regards to the vaccine and the general public looks like they’re not being trusted with the related info.
The CDC and FDA are in a little bit of a “damned should you do, damned should you don’t” scenario, however I’ve been actually impressed with how a variety of specialists have tried to speak the scenario as clearly as they will, and actually stress the purpose that we will make better-informed choices with this info being publicly on the market.